{"id":33120,"date":"2012-11-15T10:02:23","date_gmt":"2012-11-15T15:02:23","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=33120"},"modified":"2012-11-15T10:02:23","modified_gmt":"2012-11-15T15:02:23","slug":"in-acute-vte-novel-oral-anticoagulants-and-conventional-therapy-show-similar-efficacy","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/11\/15\/in-acute-vte-novel-oral-anticoagulants-and-conventional-therapy-show-similar-efficacy\/","title":{"rendered":"In Acute VTE, Novel Oral Anticoagulants and Conventional Therapy Show Similar Efficacy"},"content":{"rendered":"<p>Novel oral anticoagulants and vitamin K antagonists offer similar protection against venous thromboembolism recurrence, according to <a href=\"http:\/\/www.bmj.com\/content\/345\/bmj.e7498\">a <em>BMJ<\/em> meta-analysis<\/a>. However, one of the newer agents, rivaroxaban, seems to offer better protection against bleeding.<\/p>\n<p>The analysis included nine randomized controlled trials comparing apixaban, dabigatran, rivaroxaban, or ximelagatran (no longer on the market) with traditional vitamin K antagonists (e.g, warfarin) in nearly 17,000 patients with acute VTE. Follow-up ranged from 2 weeks to 12 months.<\/p>\n<p>There were no significant differences between any of the novel anticoagulants and vitamin K antagonists with respect to recurrent VTE or all-cause mortality. The newer agents tended to lower the risk for major bleeding, but only the effect of rivaroxaban was statistically significant. An indirect comparison between rivaroxaban and dabigatran did not favor either drug for any outcome.<\/p>\n<p>Asked to comment, David Green of <em>Journal Watch Oncology and Hematology<\/em> said: &#8220;The benefits of the new oral anticoagulants are that monitoring is not required and there are fewer interactions with other drugs; the downside is that there are no readily available reversing agents and experience is still accumulating about effectiveness and safety in various populations.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novel oral anticoagulants and vitamin K antagonists offer similar protection against venous thromboembolism recurrence, according to a BMJ meta-analysis. However, one of the newer agents, rivaroxaban, seems to offer better protection against bleeding. The analysis included nine randomized controlled trials comparing apixaban, dabigatran, rivaroxaban, or ximelagatran (no longer on the market) with traditional vitamin K [&hellip;]<\/p>\n","protected":false},"author":577,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,7],"tags":[1543,1154,747],"class_list":["post-33120","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-prevention","tag-anticoagulants","tag-oral-anticoagulants","tag-venous-thromboembolism"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/577"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=33120"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33120\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=33120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=33120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=33120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}